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Introduction
Menopause is a biologic process that occurs as part 
of aging in women. Aging is the natural progression of
changes in structure and function in body systems that
occurs as a function of the progress of time and in the
absence of disease [1]. Therefore, menopause should
not be considered as a disease, although menopause can
be induced either by medical or surgical ablation of the
ovarian function as a result of some diseases. However,
menopause results in a hypoestrogenic state of the body,
and subsequently may adversely affect estrogen target
tissues, including the brain, skeleton and skin, as well as
the cardiovascular and genitourinary systems [2]. The
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SUMMARY
Menopause occurs naturally when the ovary ceases folliculogenesis, or artificially by surgical and/or medical
ablation of the ovarian function. Menopause is a hypoestrogenic state, which may adversely affect estrogen tar-
get tissues, such as the brain, skeleton and skin, as well as the cardiovascular and genitourinary systems, with
resultant frequency and severity of climacteric symptoms. The climacteric symptoms, however, vary significantly
among women. For decades, hormone therapy (HT) has been the mainstay and is considered the most effective
for managing menopausal symptoms. The prolonged use of either single estrogen therapy or a combination
therapy of estrogen and progestogen (EPT) might be associated with a slightly increased risk of breast cancer
and many resultant adverse events, such as coronary heart disease, stroke and venous thromboembolism.
Perhaps because the clear benefits are limited to these end points of HT in treating menopausal women, the rel-
atively significant adverse event profiles of these women may not be enough to trigger primary care physicians
to be more aggressive than they have been to date in treating climacteric symptoms of postmenopausal women.
However, severe climacteric symptoms really disturb the woman’s life. Some epidemiologic studies have shown
that the increased risk for breast cancer after 5 years of combined EPT is similar in magnitude to other lifestyle
variables, such as 10-year delayed menopause, fewer pregnancies and reduced breastfeeding, postmenopausal
obesity, excessive alcohol or cigarette use, and lack of regular exercise. Furthermore, elevated serum concentrations
of either endogenous or exogenous (replaced by HT) sex hormone in either pre- or postmenopausal women are
associated with an increased risk of breast cancer. Finally, the increased breast cancer risk diminishes soon after
discontinuing hormones, and largely disappears by 5 years after cessation. Taken together, low-dose conven-
tional HT can be used with symptomatic menopausal women, but is worthy of further evaluation because we
found the following potential benefits, including (i) low-dose oral EPT appears to be effective for the alleviation
of climacteric symptoms; (ii) it has a good tolerability profile with a low incidence of the most common and
problematic side effects, such as breast tenderness and an increased mammographic density. Altogether, when com-
pared with the standard dose HT, physicians may prefer to use low-dose HT initially in managing the climacteric
symptoms of postmenopausal women. Time will prove. [Taiwan J Obstet Gynecol 2007;46(2):127–134]
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reaction of target tissues to estrogen deficiency, with
the resultant frequency and severity of climacteric symp-
toms varies significantly among women [3]. These cli-
macteric symptoms frequently bother perimenopausal
(the menopausal transition) and/or postmenopausal
women, resulting in severe interference in their quality of
life [4,5]. There are two broad categories of menopausal
hormone therapies (HTs): estrogen therapy (ET) alone
and combined estrogen with progestin therapy (EPT) [2].
Although HT is the mainstay therapy for sympto-
matic postmenopausal women, concerns have arisen
regarding the possible association of breast cancer and
HT. An association between breast cancer and hormone
use would be plausible because breast cancer incidence
is increased by hormonal factors, such as early menar-
che and late menopause [6]. A summary of 51 epidemio-
logic studies, enrolling 161,116 women with breast
cancer and hormone use, showed that breast cancer
risk increased by 2.3% per year of hormone use (mostly
estrogen use), compared with an increased risk of 2.8%
per year of natural delay in the onset of menopause [7],
suggesting that hormone use increases the risk of devel-
oping breast carcinoma and that this risk increases with
the increasing duration of hormone use [2]. A review of
19 epidemiologic studies estimated the average breast
cancer risks to be 1.18 (95% confidence interval [CI],
1.01–1.38) with current use of ET, and 1.70 (95% CI,
1.36–2.17) with current use of EPT [8]. Taken together,
hormone, of either endogenous origin or from exoge-
nous replacement, is correlated with an increased risk of
breast cancer. However, some women suffer from per-
sistent and intolerable vasomotor symptoms that are
intractable to other alternative therapy and respond
only to prescription therapy. How should we deal with
these patients? The following will offer recent opinion
and/or evidence addressing the use of HT in sympto-
matic postmenopausal women.
Estrogens and Progestins
The prescribed hormones are relatively complicated, and
many products are available in the market. For example,
estradiol is available in oral, transdermal, injectable
and vaginal delivery systems [9]. To be absorbed orally,
estradiol must be micronized. Once absorbed, estra-
diol is converted in the liver to estrone [10]. In contrast,
transdermal application avoids hepatic “first pass”
metabolism, resulting in sustained concentrations of
estradiol [10]. Delivery systems for transdermal applica-
tion include reservoir patches that have a pouch in which
estradiol is dissolved in alcohol once or twice weekly, and
a gel formulation that is applied to the skin daily. The
matrix patches contain an adhesive matrix, in which the
estradiol is dissolved and the gel is absorbed into the
skin in 1 to 2 minutes and serum concentrations reach
a steady state after the third daily administration [9].
One type of estrogen is known as conjugated estro-
gens (CEs), which are a blend of estrogens that can be
chemically produced or derived from plant or animal
sources [6]. Among the CEs, conjugated equine estro-
gens (CEEs) may be one of the best-known products.
Other types of estrogens available in the market are
ethinylestradiol (EE2) and estropipate [9]. The syn-
thetic agonists EE2 and diethylstilbestrol were found to
be considerably more potent than the natural CEE,
estradiol (E2) and piperazine estrone sulfate [11].
However, potency by weight is not a significant factor
in deciding the suitability of a drug for use in a clinical
preparation. The situation is made more complex by
the interconversion of different estrogenic compounds
that are more or less potent. Estradiol valerate (E2V), for
example, is rapidly hydrolyzed to E2 during first-pass
hepatic metabolism. E2 is interconvertible with the less
potent estrone (E1), and vice versa, by oxidation/
reduction, and each can be irreversibly converted to
estriol (E3) [11].
Similar to the abovementioned for estrogen, there
are many progestin products available on the market,
and they can be easily separated into two different
classes: one is 17α-hydroxyprogesterone derivatives (in-
cluding medroxyprogesterone acetate [MPA], megestrol,
and progesterone), and the other is 19-nortestosterone
derivatives (norethindrone, norgestimate [NGM], and
norethindrone acetate [NETA]). A variety of progestins
are used in EPT preparations. Besides the progesto-
genic effect which all progestins have in common, there
is a wide range of biologic effects (anti-gonadotropic,
anti-estrogenic, estrogenic, androgenic, anti-androgenic,
glucocorticoid, anti-mineralocorticoid, sedative) which
differ for the various progestins [12]. Amongst these
various biologic activities, an issue of clinical signifi-
cance is androgenicity. Whilst the androgenic properties
of some progestogens could antagonize the beneficial
effects of estrogen in HT [13], some androgenic effects
may be welcome [14]. In general, the androgenic effects
of progestogens used in HT are weak, but the differ-
ences between them may be clinically significant [15].
For example, deterioration in glucose tolerance, increases
in low-density lipoprotein levels, and reductions in high-
density lipoprotein levels all correlate with increasing
androgenic potency (levonorgestrel [LNG] > NETA >
MPA) [16].
Besides the above classification, one novel product,
drospirenone [DRSP], which is unlike other currently
available progestins, has a pharmacologic profile which
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closely mimics that of endogenous progesterone, most
notably its potent anti-aldosterone and anti-androgenic
effects [17]. Consequently, DRSP, when combined with
17β-estradiol (17β-E2) as HT, offsets E2-related water
and sodium retention by blocking the mineralocorticoid
receptor [17]. The majority of progestins used in the
market are oral form. Natural form progesterone can
be used through either the oral or vaginal route.
Prescription HT for Relieving the
Climacteric Symptoms of 
Postmenopausal Women
The most commonly prescribed hormone is estrogen,
either alone ET or combined with a progestin EPT for
women with a uterus [18]. The principal indication for
the use of EPT is the presence of a uterus.
A meta-analysis of 21 randomized, double-blind,
placebo-controlled trials found that systemic ET/EPT
significantly reduced both hot flash frequency and sever-
ity compared with a placebo, with a reduction rate of up
to 77% and 87%, respectively [19]. A recent report of
the Women's Health Initiative (WHI) study lent further
evidence to the above finding, which showed that 85.7%
of subjects on EPT, compared with 57.7% of women
on a placebo, had relief of hot flashes, and 77.6% of
subjects on EPT, compared with 57.4% of women on a
placebo, had relief of night sweats [20]. There are many
ET/EPT preparations with different routes of adminis-
tration, regimens, and doses available in our clinical
practice. So far, there is an absence of evidence showing
that one product or regimen is superior to another for
symptom relief. Patch and gel formulations are equally
effective in treating vasomotor symptoms (VMS) and
the effects are comparable to those achieved by oral
ET/EPT [21]. In addition, the dose–response relation-
ship between EPT and symptomatic relief seems not to
exist [18]. A large randomized, multi-center, placebo-
controlled trial showed that the reduction in VMS was
similar with a daily standard dose containing 0.625-mg
CEE and 2.5-mg MPA, and all lower combination doses
[22]. In contrast, a dose–response relationship seems
to exist with ET alone, because the same study found
that 0.625-mg CEE per day alleviated hot flashes more
effectively than the lower doses of CE alone. Moreover,
an ET/EPT trial of 4 weeks or longer may be required to
obtain the full effect on VMS. However, a systemic prog-
estin may be added to an ET regimen if a hysterectomized
woman presents persistent vasomotor symptoms on
standard or higher doses of estrogens (≥ CEE 0.625 mg/
day or equivalent). The 2002 North American Meno-
pause Society Advisory Panel Report recommended
the use of lower-than-standard doses of HT for manag-
ing climacteric symptoms of postmenopausal women,
and because hot flashes (climacteric symptoms) affect
about three-quarters of Caucasian women [23], it seems
preferable to use the lowest dose of oral or transdermal
HT that adequately controls VMS [24].
Conventional HT and Risk of Breast
Cancer in Postmenopausal Women
Data have accumulated in randomized clinical trials, to
date, involving more than 30,000 women and in epidemi-
ologic studies involving more than 1.8 million women
[3,8]. With ET use, the average risk of invasive breast
cancer was 0.81 (95% CI, 0.63–1.03) in four randomized
trials involving 12,643 women [25–28]. With EPT use,
the average breast cancer risk was 1.24 (95% CI, 1.03–
1.50) in randomized trials involving 19,756 women
[29–33]. The absolute effect of EPT in the WHI and
heart and estrogen/progestin replacement study trials
added 8 and 17 cases per 10,000 women per year,
respectively, to natural risk [31,32]. Data from the Mil-
lion Women Study (MWS) showed the increased risk
to current users of ET, EPT, and tibolone as 1.30 (95%
CI, 1.21–1.40; p < 0.0001), 2.00 (95% CI, 1.88–2.12; 
p < 0.0001), and 1.45 (95% CI, 1.25–1.68; p < 0.0001),
respectively, but the magnitude of the associated risk was
substantially greater for EP than for other types of HT
(p < 0.0001) [34]. In six epidemiologic studies, includ-
ing the MWS, the average relative risks with sequential
and continuous progestin regimens were 1.85 (95% CI,
1.72–1.99) and 1.94 (95% CI, 1.78–2.11), respectively,
a difference that was not significant [8].
Some epidemiologic studies showed that the
increased risk for breast cancer after 5 years of com-
bined EPT was similar in magnitude to other lifestyle
variables, such as 10-year delayed menopause, fewer
pregnancies and reduced breastfeeding, postmenopausal
obesity, excessive alcohol or cigarette use, and lack of
regular exercise [9]. Furthermore, elevated serum endoge-
nous sex hormone concentrations in premenopausal
women are associated with an increased risk of breast
cancer [1]. Kaaks’ studies showed that increased risks
of breast cancer were associated with elevated serum
concentrations of testosterone (odds ratio [OR] for
highest vs. lowest quartile, 1.73; 95% CI, 1.16–2.57;
p = 0.01), androstenedione (OR for highest vs. lowest
quartile, 1.56; 95% CI, 1.05–2.32; p = 0.01), and dehy-
droepiandrosterone sulfate (DHEAS) (OR for highest vs.
lowest quartile, 1.48; 95% CI, 1.02–2.14; p = 0.10), but
not sex hormone-binding globulin (SHBG). Elevated
serum progesterone concentrations were associated
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with a statistically significant reduction in breast cancer
risk (OR for highest vs. lowest quartile, 0.61; 95% CI,
0.38–0.98; p = 0.06). The absolute risk of breast can-
cer for women younger than 40 years followed up for 
10 years was estimated at 2.6% for those in the highest
quartile of serum testosterone vs. 1.5% for those in the
lowest quartile; for the highest and lowest quartiles of
progesterone, these estimates were 1.7% and 2.6%,
respectively. Breast cancer risk was not statistically sig-
nificantly associated with serum levels of the other
hormones [35]. In addition, endogenous sex hormone
concentrations were also associated with breast cancer
risk among postmenopausal women not using post-
menopausal hormones [36]. Missmer’s group observed a
statistically significant direct association between breast
cancer risk and the levels of both estrogen and andro-
gen, but did not find any (by year) statistically significant
associations between this risk and the level of proges-
terone or SHBG. When they restricted the analysis to
case subjects with ER+/PR+ tumors and compared the
highest with the lowest fourths of plasma hormone
concentration, they observed an increased risk of breast
cancer associated with E2 (relative risk [RR], 3.3; 95%
CI, 2.0–5.4), testosterone (RR, 2.0; 95% CI, 1.2–3.4),
androstenedione (RR, 2.5; 95% CI, 1.4–4.3), and DHEAS
(RR, 2.3; 95% CI, 1.3–4.1). In addition, all hormones
tended to be associated most strongly with in situ dis-
ease. Therefore, they concluded that circulating levels of
sex steroid hormones may be most strongly associated
with risk of ER+/PR+ breast tumors [36]. Tworoger’s
group studied serum levels of sex hormones in post-
menopausal hormone users and found that these women
had statistically significantly higher estradiol, free estra-
diol, SHBG and testosterone, and lower free testosterone
concentrations than non-postmenopausal hormone
users [37]. After evaluating the relationship between
hormone levels and breast cancer risk, they found mod-
est associations with breast cancer risk when comparing
the highest vs. lowest quartiles of free E2 (RR, 1.7; 95%
CI, 1.1–2.7; p = 0.06), free testosterone (RR, 1.6; 95%
CI, 1.1–2.4; p = 0.03), and SHBG (RR, 0.7; 95% CI,
0.5–1.1; p = 0.04), but not of E2 or of testosterone.
However, E2 and free E2 were statistically, significantly,
and positively associated with breast cancer risk among
women older than 60 years (RR, 2.8; 95% CI, 1.5–5.0;
p = 0.002; and RR, 2.6; 95% CI, 1.4–4.7; p = 0.001,
respectively), and among women with a body mass
index of less than 25 kg/m2 (RR, 1.8; 95% CI, 1.1–3.1;
p = 0.01; and RR, 2.4; 95% CI, 1.4–4.0; p = 0.003,
respectively). Therefore, they concluded that although
women using postmenopausal hormone have a different
hormonal profile than those not using postmenopausal
hormone, plasma sex hormone concentrations appear
to be associated with breast cancer risk among post-
menopausal hormone users [37], suggesting the possi-
ble benefits of using low-dose effective hormone in
managing these symptomatic postmenopausal women
because the low-dose HT may contribute to the low
serum levels of hormone, which may contribute to lower
breast cancer risk.
In addition, in the epidemiologic studies, the
increased breast cancer risk diminished soon after dis-
continuing hormones, and it largely disappeared by 
5 years after cessation [8]; the use of HT as a standard
treatment applied to all menopausal women will not
meet the needs of many individual women [1]. Health
care providers should therefore consider the relative
balance between the benefits and risks of treatment
for each patient before drawing conclusions or recom-
mending HT. Therefore, as with the abovementioned,
alternative dosage and application methods, such as
oral low-dose HT and ultra-low dose transdermal HT,
which deliver the benefit but not the adverse side effects,
would be clinically advantageous, although Collins’
group found that breast cancer risk did not vary signif-
icantly with different types of estrogen or progestin
preparations, with use of lower dosages or with differ-
ent routes of administration [8]. Crandall [24] also
announced that low-dose preparations should not yet
be emphasized as being safer than traditional doses.
In order to understand the role of low-dose HT in
the breast in postmenopausal women, it is appropriate
to review the available data about the risk of breast
cancer with low-dose HT in treating climacteric symp-
toms of postmenopausal women.
The Climacteric Symptoms in
Postmenopausal Women
Some of the major climacteric symptoms of post-
menopausal women may be related to VMS. The VMS
associated with menopause are commonly termed hot
flashes and night sweats [18]. Hot flashes are character-
ized by the sudden onset of intense warmth that begins
in the chest and may progress to the neck and face [38].
They are often accompanied by anxiety, palpitations, and
profuse sweating. VMS may interfere with a woman’s
ability to work, her social life, her sleep pattern, and her
general perception of health. VMS are an early, readily
apparent sign of menopause transition, and the maximal
prevalence is during the first 2 years of postmenopause,
after which the prevalence declines over time. Most
women experience hot flashes for 6 months to 2 years,
although some women have them for 10 years or
longer [18]. The study of women’s health across the
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nation demonstrates the different prevalence rates of hot
flashes among racial/ethnic groups. According to this
multiethnic cross-sectional survey of more than 16,000
women aged 40–55, African-American women report
hot flashes most frequently, followed by Hispanics,
Caucasians, Chinese, and Japanese [39]. Multiple treat-
ments have been used to relieve hot flashes, including
lifestyle modifications, and non-prescription and pre-
scription therapies [18]. Multiple placebo-controlled tri-
als have shown about 25–30% reduction in hot flashes
within 4 weeks of placebo treatment [38]. In addition,
a Cochrane review of ET compared with a placebo for the
treatment of hot flashes has shown that a placebo may
cause a VMS reduction of up to 50% [40]. And finally,
the menopausal state is a natural course, an aging
process, and of most importance, it is not a disease.
Therefore, we must take into account health status and
personal choice when assisting postmenopausal women
with mild to moderate VMS. We prefer the use of life
modification as a first choice strategy for relieving mild-
to-moderate VMS; life modification includes manipu-
lating the environment and changing behaviors. After
introducing non-medication therapy, many women with
persistent VMS still respond only to HT. The following
addresses the efficacy of low-dose HT in managing 
climacteric symptoms.
The Efficacy of Low-dose HT in 
Relieving Climacteric Symptoms in
Postmenopausal Women
Before entering into the topic of the efficacy of low-dose
HT in relieving climacteric symptoms, the definition of
low-dose should be clarified. Based on the published
data [11,24], a low-dose of estrogens was considered
to be (at most) 0.3 mg CEE, 25–75 µg transdermal 
E2, 0.05–1 mg oral E2, 1 mg E2V, 0.3 mg esterified
estrogens (EE), 5 µg EE2, and 0.3 mg synthetic CE.
Dosages of progestogens used in low-dose cc-HT for-
mulations are shown as follows: MPA 1.5–5 mg/day;
LNG 5–20 µg/day; NETA 0.1–1.0 mg/day; dydroges-
terone 5 mg/day; nomegestrol 2.5 mg/day; trimegestone
0.125 mg/day; DRSP 2 mg/day [11]. Likewise, in gen-
eral, all low-dose regimens appear to be highly effective
in the management of climacteric symptoms, with no
consistently significant differences in the magnitude of
the effect of conventional dose regimens [22,41–44].
However, some studies have reported a slight dose–
response effect with EE2/NETA [45], both in terms of
overall efficacy and time to onset of response. Although
head-to-head comparisons are lacking, there is no 
evidence of any marked differences between different
low-dose regimens. In a recent excellent review sum-
marizing the results of low-dose estrogens for relieving
VMS [24], there was a comparable efficacy of 25 µg
and higher doses of transdermal E2 for VMS, and a
dose-related trend in the proportion of severe hot flashes.
However, there was a possible lag of a few weeks in the
onset of effect, compared with higher doses. Synthetic
CE may be efficacious by 4 weeks, but it is not clear how
different doses compare with each other. E2/NGM 1 mg/
90 µg is efficacious. Low doses of CEE/MPA (0.45/2.5,
0.45/1.5, 0.3/1.5 mg) are as effective as traditional
doses, but with a week’s lag. MPA adds to the efficacy
of low-dose CEE, blunting the dose–response seen with
low-dose CEE alone. CEE 0.3 mg/day is efficacious,
although some older women may experience a flare-up
in VMS when switching to CEE 0.3 mg/day plus cycli-
cal MPA from 0.625 mg CEE. E2/NETA 1 mg/0.5 mg
and 1 mg/0.25 mg have comparable efficacy, both to
each other and to higher doses at 4 weeks. EE2/NETA
1 µg/5 mg is efficacious, but there is a lag of 1 week in
therapeutic efficacy vs. higher doses, and a clear dose–
response relationship. E2 alone 0.5 mg/day is effica-
cious for hot flashes, but response is dose-related in a
range of 0.25–2 mg. An E2 dose of 0.25 mg/day is not
adequate for suppression of hot flashes, and 0.5 mg
may not be superior to a placebo.
In summary, evidence from well-conducted long-term
oral EPT clinical trials has confirmed that low-dose EPT
preparations are effective in alleviating climacteric symp-
toms, and that this effect was not influenced to a clin-
ically relevant degree by the presence of progestins [11].
But for the estrogen-only group, the efficacy of lower
doses of estrogen for the reduction of VMS may be less
than a daily standard dose containing 0.625 mg CEE
[28]. The effect on climacteric symptoms is sustained
over long-term use.
Breast Tenderness of Women who are
Treated with Low-dose HT
According to the above review [24], breast pain can
occur with synthetic CE (about one third, but there is a
lack of data by dose), with E2 in doses of > 0.5 mg
(25% with 0.5 mg), and with E2/NETA (2% with 1 mg/
0.5 mg). Breast tenderness is less frequent with oral E2
0.25 mg/day compared with higher doses. E2/NETA,
1 mg/0.5 mg is associated with less breast pain vs.
higher doses. No matter which dose is used, about 20%
of subjects experience breast tenderness with E2/NGM,
and adding NGM to E2 raises the rate of breast tender-
ness. Breast tenderness with CEE/MPA is dose-related,
with an incidence of about 10% with 0.3 mg/2.5 mg.
Taiwan J Obstet Gynecol • June 2007 • Vol 46 • No 2 131
HT in Postmenopausal Women
Breast tenderness with transdermal E2 is also dose-
related, ranging from 20% to 65% with low doses in dif-
ferent trials. In summary, low-dose HT will result in a
lower frequency of breast tenderness when compared
with standard HT.
Mammography Changes in Women 
who are Treated with Low-dose HT
An increase in mammographic density should be
regarded as an unwanted side effect of HT, because
increased breast density can impair interpretation of
mammograms, thus increasing the failure rate of breast
cancer screening programs [2]. Greendale et al [46]
studied mammographic density changes in 571 women
aged 45–64 years, who were enrolled in the post-
menopausal estrogen/progestin interventions trial and
randomly assigned to receive a placebo, daily CEE at
0.625 mg/day, daily CEE and MPA at 10 mg/day on
days 1–12 (CEE + MPA-cyclic), daily CEE and MPA at
2.5 mg/day (CEE + MPA-continuous), or daily CEE
and micronized progesterone (MP) at 200 mg/day on
days 1–12 (CEE + MP), using digitized mammograms
to determine the percentage of the left breast that was
composed of dense tissue (i.e. mammographic per-
cent density). They found that the adjusted absolute
mean changes in mammographic percent density over
12 months were 4.76% (95% CI, 3.29–6.23%), 4.58%
(95% CI, 3.19–5.97%), and 3.08% (95% CI, 1.65–
4.51%) for women in the CEE + MPA-cyclic, CEE +
MPA-continuous, and CEE-MP groups, respectively.
Each of those absolute mean changes was statistically
significantly different from the adjusted absolute mean
change in mammographic percent density for women
in the placebo group, which was −0.07% (95% CI, 
−1.50–1.38%). Therefore, they concluded that greater
mammographic density was associated with the use of
estrogen/progestin combination therapy, regardless of
how the progestin was given, but not with the use of
estrogen only [46]. A follow-up WHI mammogram den-
sity study (using a standard dose of hormone) showed
that mean mammographic percent density increased
by 6.0% at year 1, compared with baseline, in the EPT
group, but decreased by 0.9% in the placebo group
(difference, 6.9%; 95% CI, 5.3–8.5%; p < 0.001) [47].
The mean changes in mammographic density persisted
but were attenuated slightly after 2 years, with an
absolute increase of 4.9% in the EPT group and a de-
crease of 0.8% in the placebo group (difference, 5.7%;
95% CI, 4.3–7.3%; p < 0.001). These effects were consis-
tent across racial/ethnic groups but were higher among
women aged 70–79 years in the EPT group (mean
increase at year 1, 11.6%) than in the placebo group
(mean decrease at year 1, 0.1%) (difference of the
means, 11.7%; 95% CI, 8.2–15.4%; p < 0.001, compared
across age groups). At year 1, women who were adher-
ent to treatment in the EPT group had a mean increase
in density of 7.7% (95% CI, 5.9–9.5%), and women in
the placebo group had a mean decrease in density of
1.1% (95% CI, 0.3–1.9%). Use of EPT was associated
with an increased risk of having an abnormal mammo-
gram at year 1 (RR, 3.9; 95% CI, 1.5–10.2; p = 0.003),
compared with a placebo, which was not explained by
the increase in density [47]. Lundstrom et al [48] eval-
uated a total of 158 women who were treated with 
different regimens of HT and found that an increase 
in mammographic density was much more common
among women taking continuous EPT (40%) than for
those using oral low-dose estrogen (6%) and transder-
mal (2%) treatment, and the increase in density was
already apparent at the first visit after starting HT.
During long-term follow-up, there was very little change
in mammographic status. Sendag et al [49] found that
mammographic breast density changes related to post-
menopausal HT are dependent on the selected hormone
regimen, and the continuous administration of the prog-
estin component of the EPT seems to effect the breast
density most. Christodoulakos et al [50] found an
increase in breast density in 13.2%, 31.8%, and 12.2%
of women (5/38) treated with CE/MPA, E2/NETA,
and low E2/NETA, respectively, and no woman exhib-
ited an involution of fibroglandular tissue, suggesting
that different HT regimens have a variable impact on
breast density, probably depending on the steroid used,
and low-dose HT is associated with significantly less of
an increase in breast density. Conner’s group further
studied the effects of different regimens of EPT [51]
and found an increase in mammographic density in
approximately 50% of the women; there were no differ-
ences between the treatments. Increased density showed
a positive correlation with estradiol, estrone, and SHBG
and showed a negative association with free testos-
terone. Among hormonal factors, levels of free testos-
terone were the most important for predicting increased
density. Therefore, the researchers concluded that con-
tinuous EPT with different progestogens has a marked
impact on the breast [51]. Since progestins played a
major role in the increased risk of mammographic density
in the EPT group, some investigators have used a low-
dose intrauterine system releasing 20 µg/24 hours of
LNG in continuous combination with 2 mg of oral E2V
to decrease the progestin stimulation on the breast
without compromising uterine protection [52]. As
expected, there was no increase in proliferation as
expressed by the percentage of MIB-1-positive breast
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cells in fine-needle aspiration biopsies. However, the
increase in breast density displayed a positive correla-
tion with patient age (rs, 0.52) and an inverse relation-
ship with levels of E2 (rs, –0.50) and free testosterone
(rs, –0.50) [52]. Therefore, they concluded that low-
dose intrauterine administration of progestogen may
develop into an attractive alternative for HT in post-
menopausal women, as endometrial protection may be
achieved at very low systemic levels [51]. Junkermann’s
group compared continuous low-dose HT and stan-
dard-dose sequential HT and found that there were no
marked differences between treatment groups, because
approximately 20% of women in both groups had a slight
increase in mammographic density [53]. Overall, there
is a great deal of evidence showing that the estrogen-
only group and the low-dose progestin in EPT group may
have less of an increase in the mammographic density,
although more strong evidence is required to support
these findings.
Conclusion
Low-dose oral EPT appears to be effective for the alle-
viation of climacteric symptoms. It has a good tolera-
bility profile with a low incidence of the most common
and problematic side effects such as breast tenderness
and increased mammographic density. However, regard-
ing the long-term effects of different low-dose EPT on
cardiovascular disease, and cerebrovascular events, and
breast cancer incidence; more long-term data and direct
head-to-head comparisons between the various low-
dose preparations are needed. Taken together, physi-
cians may prefer using low-dose HT initially, rather than
standard dose HT, in managing the climacteric symp-
toms of postmenopausal women.
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